[8-K] Kyverna Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Kyverna Therapeutics, Inc. furnished a press release providing a business update and reporting financial results for the quarter ended June 30, 2025. The press release is attached to the report as Exhibit 99.1.

The company notes this information is furnished, not filed, and therefore is not subject to Section 18 liability and is not automatically incorporated by reference into registration statements. Kyverna's common stock trades on Nasdaq under the symbol KYTX, and the registrant is identified as an emerging growth company.

Insights

Financial Analyst

TL;DR: This 8-K furnishes a Q2 2025 press release but contains no financial figures here, so its standalone investor impact is indeterminate.

The filing states that a press release containing a business update and financial results for the quarter ended June 30, 2025 has been furnished as Exhibit 99.1. Because the content provided here does not include the press release text or numeric results, no assessment of revenue, earnings, margins or guidance can be made from this document alone. The legal designation that the material is "furnished, not filed" is explicit and limits Section 18 liability. Rating: 0 (Neutral). Impact assessment: not impactful absent the exhibit's details.

Corporate Governance Expert

TL;DR: The disclosure is procedural; furnishing the press release signals transparency but does not itself alter governance or operational facts.

The 8-K confirms the company provided a business update and Q2 financial results via a press release attached as Exhibit 99.1. The registrant is marked as an emerging growth company. The filing explicitly states the press release is furnished rather than filed, which is a common practice to disclose material communications while limiting certain liabilities. Based solely on this filing, there is no evidence of a governance change or material corporate action. Rating: 0 (Neutral). Impact assessment: not impactful without the exhibit content.

false000199470200019947022025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

Kyverna Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41947	83-1365441
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
5980 Horton St., STE 550
Emeryville, California				94608
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 925-2492

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		KYTX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Kyverna Therapeutics, Inc. (the “Company”) issued a press release providing a business update and reporting financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”).

In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release issued by Kyverna Therapeutics, Inc. dated August 12, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		KYVERNA THERAPEUTICS, INC.
Date: August 12, 2025		By:	/s/ Warner Biddle
			Warner Biddle
			Chief Executive Officer

FAQ

What did Kyverna (KYTX) disclose in this 8-K?

The company furnished a press release providing a business update and financial results for the quarter ended June 30, 2025, attached as Exhibit 99.1.

Is the press release in this 8-K considered "filed" or "furnished"?

The 8-K states the press release is furnished, not filed, and therefore it is not subject to Section 18 liability and is not automatically incorporated by reference.

Where can I find the press release referenced by Kyverna?

The filing lists the press release as Exhibit 99.1 to the current report; the exhibit should contain the full press release and financial details.

What reporting period do the results cover in the disclosed press release?

The press release reports financial results for the quarter ended June 30, 2025.

What exchange and ticker does Kyverna use?

Kyverna Therapeutics' common stock is listed on Nasdaq under the ticker KYTX.

Does the filing indicate Kyverna is an emerging growth company?

Yes, the registrant has indicated it is an emerging growth company.